Q-omics provides the consensus-scored ANKRD44 profile across patient tissues and cancer cell-line models. ANKRD44 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ANKRD44 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, ANKRD44 protein abundance shows 28,278 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, BLCA, and LSCC as cancer lineages where ANKRD44 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD44 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD44 survival associations across molecular data types. ANKRD44 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD44 RNA expression–survival associations across cancer types. High ANKRD44 expression shows unfavorable associations in ACC and UVM, but favorable associations in HNSC, LUAD, UCS and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ANKRD44 RNA expression.
This table summarizes ANKRD44 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ANKRD44. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD44 shows lower tumor expression in BLCA, LUSC, LUAD, COAD and UCEC and higher tumor expression in KIRC. The BLCA box plot shows higher ANKRD44 RNA expression in normal versus tumor tissue (log2 FC = −0.953, t-test p < 0.001).
This table shows molecular features associated with ANKRD44 in patient tissues and cancer cell lines. In patient samples, ANKRD44 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD44 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
